Repare Therapeutics is reportedly within days of disclosing its plans to go public. (The Globe and Mail)
Repare Therapeutics is reportedly within days of disclosing its plans to go public. (The Globe and Mail)
Repare Therapeutics is reportedly within days of disclosing its plans to go public. (The Globe and Mail)
Talking point: Repare would be the first Canadian biotech company to list on the Nasdaq in a year. Its potential success comes on the heels of Vancouver-based biotech firm AbCellera, which raised US$105 million earlier this week. Repare raised US$82.5 million in September 2019 to create drugs targeting cancerous tumours. The firm is now looking to get into human clinical trials by the summer. Listing on the Nasdaq is typical for early-stage drug developers, but Repare’s move would come despite a number of Canadian institutional investors seeking to get into biotech. In November 2019, for example, the Business Development Bank of Canada spun out a fund looking to raise $200 million to invest in the sector.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.